• S Tag Peptide: Solubility and Detection Protocol

  2026-09-21

  S Tag Peptide (SKU A6007) is a soluble 15-amino-acid RNase A-derived peptide used for S-peptide fusion tag design, recombinant protein detection, and antibody-based purification workflows. It is appropriate for aqueous protein engineering applications but should not be treated as an independently active enzyme or used in ethanol-based systems.

• Preserving OXPHOS Evidence at the Extraction Edge

  2026-09-21

  The LRPPRC–dasatinib study highlights how complementary disruption of nuclear- and mitochondrial-encoded OXPHOS programs can reveal therapeutic vulnerabilities. This thought-leadership guide explains why extraction quality is a translational control point and how an EDTA-free, broad-spectrum inhibitor strategy can protect the protein evidence behind those conclusions.

• Translational Logic for Cas12a mRNA Editing

  2026-09-20

  A mechanistic and strategic guide to evaluating Cas12a mRNA workflows, connecting PAM geometry, guide engineering, modified RNA, delivery, and orthogonal editing assays with translational decision-making.

• Rucaparib (AG-014699) in DNA Repair Assays

  2026-09-19

  Rucaparib (AG-014699) is a practical PARP1 probe for connecting DNA damage, repair deficiency, and radiation response in cancer models. This workflow combines dose-response testing, γ-H2AX and p53BP1 imaging, clonogenic survival, and spliceosome-linked biomarker analysis for more informative cancer research.

• HBTU Workflow for Bioluminescent Peptide Probes

  2026-09-18

  HBTU combines rapid carboxylic acid activation with a practical, racemization-resistant route for assembling complex peptide probes. This workflow connects solid phase peptide synthesis with the caged bioluminescent immunoproteasome assays described in the reference study, while separating chemistry validation from biological interpretation.

• Magnetic CAR-T Mimicry for Solid Tumors

  2026-09-18

  The reference study introduces a magnetic bispecific nano-antibody that engages endogenous T cells in vivo, gives them CAR-T-like targeting behavior, and guides their migration toward solid tumors with an external magnetic field. Its significance lies in combining cell engineering, tumor recognition, and spatial control without ex vivo genetic modification, although the strategy remains preclinical and requires further validation of safety, durability, and delivery.

• VX-661: From F508del Rescue to Precision CF Research

  2026-09-17

  VX-661 is a F508del CFTR corrector that connects protein-folding rescue with proteostasis-aware cystic fibrosis research. This thought-leadership guide explains how to validate CFTR trafficking, surface expression, and channel function while interpreting calnexin-dependent, variant-specific responses.

• α-KG, LKB1–AMPK, and Periodontal Stem Cell Senescence

  2026-09-17

  This Cellular Signalling study identifies an α-ketoglutarate–LKB1–AMPK pathway that restores mitochondrial homeostasis, limits inflammation-induced senescence, and improves osteogenic function in human periodontal ligament stem cells. Combined cell and rat-model evidence positions mitochondrial recovery as a mechanistic link between metabolic intervention and periodontal regeneration, while also defining important boundaries for translation.

• Temafloxacin Activity Against Gram-Negative Bacteria

  2026-09-16

  This reference study synthesizes comparative in vitro data showing strong temafloxacin activity across respiratory, enteric, sexually transmitted, and other Gram-negative pathogens. Its main practical contribution is a species-resolved framework for interpreting MIC distributions alongside comparator drugs, organism-specific media, and the important exception of weaker activity against Pseudomonas aeruginosa.

• NIH/3T3 Cells: Recovery, Culture, and QC

  2026-09-16

  This guide provides an actionable recovery, expansion, and quality-control workflow for NIH/3T3 Cells supplied as a cryopreserved mouse fibroblast model. It supports planning for cell transfection studies, viral proliferation research, and oncogene research, but should not be used to infer quantitative performance, clinical utility, or viral permissiveness that is not established in the product dossier.

• Peripheral Macrophages Drive Pain Priming in CIH

  2026-09-15

  This study identifies peripheral macrophages as a causal component of nociceptor priming after chronic intermittent hypoxia, a mouse model of the recurrent hypoxemia associated with obstructive sleep apnea. By separating hypoxia from sleep fragmentation and testing macrophage ablation, the work connects an environmental stressor to immune remodeling in sensory tissues and persistent pain-related behavior.

• Relative Viability and Cell Killing in Cancer Assays

  2026-09-15

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability measure related but non-equivalent dimensions of anticancer drug response. Its central practical contribution is a framework for separating proliferative arrest from actual cell killing, improving endpoint selection, timing, and interpretation in in vitro cancer studies.

• gamma-Glu-Cys: A Decision Framework for Assays

  2026-09-14

  Explore how gamma-Glu-Cys and γ-Glu-Cys function as a branch-point substrate in glutathione metabolism research. This guide connects assay design, microbial γ-glutamyl peptide findings, product handling, and plant stress adaptation studies.

• BMS 309403: A Causal Map for FABP4 Research

  2026-09-14

  BMS 309403 is a selective FABP4 inhibitor for dissecting how lipid handling becomes inflammation and foam-cell pathology. This article presents a causal, assay-oriented framework based on the SERCA2–calcineurin–FoxO1–FABP4 study, distinguishing target engagement from downstream disease phenotypes.

• BCL-XL Inhibitor A-1155463: Research Workflow

  2026-09-13

  Build more informative apoptosis and resistance studies with a potent, selective BCL-XL inhibitor designed for BCL-XL-dependent cancer models. This guide translates A-1155463 pharmacology into practical cell-based, mechanistic, and in vivo workflows, with troubleshooting steps for variable response and compound handling.

8142 records 1/543 page Next 12345 下5页 Last page